PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
09-Dec-2024 Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting AccessWire
09-Dec-2024 Heidelberg University Hospital and Qlucore Present Findings on AI-based Classifiers for Lung Cancer Subtyping Heidelberg University Hospital / Qlucore
09-Dec-2024 HONEYWELL INTRODUCES LIQUID FLOW SENSING SOLUTION TO IMPROVE MEDICATION DELIVERY FOR PATIENTS AND CLINICIANS HONEYWELL
09-Dec-2024 Carta Healthcare to Power Oncology Research and Clinical Trials with Acquisition of Realyze Intelligence, a UPMC Enterprises Company Carta Healthcare
09-Dec-2024 Phastar Scoops Prestigious 2024 Scrip Award Phastar
09-Dec-2024 Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform Mestag Therapeutics
09-Dec-2024 Ingenious partners with Unfound Studio to redefine brand identity Ingenious
09-Dec-2024 Researchers use bacteria to convert plastic waste into human therapeutics, including insulin The University of Manchester
09-Dec-2024 Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting Poolbeg Pharma plc
09-Dec-2024 DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis Janssen-Cilag International NV
09-Dec-2024 PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting PureTech
09-Dec-2024 Kester Capital backs experienced management team in acquiring EMAS Pharma Kester Capital
09-Dec-2024 Bionical Emas sells EMAS Pharma to Kester Capital following strategic review Bionical Emas
09-Dec-2024 TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma Janssen-Cilag International NV
09-Dec-2024 Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Galapagos
09-Dec-2024 ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Sanofi
09-Dec-2024 Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia AccessWire
09-Dec-2024 Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) AccessWire
09-Dec-2024 Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 AccessWire
09-Dec-2024 Theralase(R) Launches Three New Clinical Study Sites in USA AccessWire